Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bayesian methods for phase I clinical trials.

C Gatsonis1, J B Greenhouse

  • 1Department of Biostatistics, Harvard School of Public Health, Boston, MA 02115.

Statistics in Medicine
|July 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fifth Ovarian Cancer Consensus Conference: individualized therapy and patient factors.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

Sample size estimation for time-dependent receiver operating characteristic.

Statistics in medicine·2013
Same author

Preventive intervention for living donor psychosocial outcomes: feasibility and efficacy in a randomized controlled trial.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2013
Same author

Validation of novel imaging methodologies for use as cancer clinical trial end-points.

European journal of cancer (Oxford, England : 1990)·2008
Same author

Meta-analysis of diagnostic test accuracy assessment studies with varying number of thresholds.

Biometrics·2004
Same author

Racial differences in cardiac revascularization rates: does "overuse" explain higher rates among white patients?

Annals of internal medicine·2001
Same journal

Optimal Weighted Tests for Replication Studies and the 'Two-Trials Rule' With Multiple Hypotheses.

Statistics in medicine·2026
Same journal

Identifiable Copula-Double-Cox Models: A Fully Parametric Framework for Dependent Right-Censored Survival Data.

Statistics in medicine·2026
Same journal

Moving From Individualized Risk-Based Prevention to Benefit-Based Prevention: Estimating Individualized Life-Years Gained From Prevention Services as a Basis for Eligibility.

Statistics in medicine·2026
Same journal

A Mixture of Distributed Lag Non-Linear Models to Account for Spatially Heterogeneous Exposure-Lag-Response Associations.

Statistics in medicine·2026
Same journal

Practical Considerations for Gaussian Process Modeling for Causal Inference in Quasi-Experimental Studies With Panel Data.

Statistics in medicine·2026
Same journal

Covariate Adjustment for Wilcoxon Two Sample Statistic and Test.

Statistics in medicine·2026
See all related articles

This study introduces a Bayesian method for estimating the maximum tolerated dose (MTD) in Phase I clinical trials. It provides updated toxicity risk assessments for patient safety and ethical study management.

Area of Science:

  • Pharmacology
  • Biostatistics
  • Clinical Trial Design

Background:

  • Phase I clinical trials are crucial for assessing drug safety and determining the maximum tolerated dose (MTD).
  • Accurate MTD estimation is essential for guiding subsequent clinical development and ensuring patient safety.
  • Traditional methods may lack flexibility in handling prior information and updating risk assessments dynamically.

Purpose of the Study:

  • To develop and evaluate a Bayesian approach for inferring the MTD in Phase I clinical trials.
  • To provide updated, patient-specific risk assessments for toxicity at various dose levels.
  • To analyze the sensitivity of MTD inferences and risk assessments to prior specifications and dose-response models.

Main Methods:

  • Utilized a Bayesian statistical framework to model the dose-response relationship.

Related Experiment Videos

  • Derived the posterior distribution of the MTD under various classes of priors.
  • Developed methods for dynamically updating toxicity risk assessments for new patients.

    • Main Results:

    • The Bayesian approach provides a robust framework for MTD estimation.
    • Posterior distributions of the MTD were obtained and their properties studied.
    • Demonstrated the utility of updated risk assessments for informed decision-making in clinical trials.

    Conclusions:

    • The proposed Bayesian methodology offers a flexible and informative approach to MTD estimation in Phase I trials.
    • Updated toxicity risk assessments enhance patient safety and ethical considerations.
    • Sensitivity analyses highlight the importance of careful prior and model selection.